Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?

PURPOSE: This review aims to provide an overview of the impact of TNFis biosimilars, with marketing authorization, in patient-reported outcome measures (PROMs) scores and explore how PROMs endpoints might add value in biosimilars uptake in RA patients. PATIENTS AND METHODS: A comprehensive search of...

Descripción completa

Detalles Bibliográficos
Autor principal: Horta-Baas, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977480/
https://www.ncbi.nlm.nih.gov/pubmed/35388274
http://dx.doi.org/10.2147/PROM.S256715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977480/
https://www.ncbi.nlm.nih.gov/pubmed/35388274
http://dx.doi.org/10.2147/PROM.S256715

Ejemplares similares